Shingrix is NOT Recommended for Healthy 22-Year-Olds
Shingrix vaccination is not indicated for a healthy 22-year-old without immunocompromising conditions. The vaccine is FDA-approved and guideline-recommended only for adults aged 50 years and older, or for adults aged 18 years and older who are immunocompromised 1.
Age-Based Recommendations
Standard Eligibility Criteria
The evidence is unequivocal across all guidelines:
- Immunocompetent adults: Shingrix is recommended starting at age 50 years 2
- Immunocompromised adults: Shingrix may be given starting at age 18 years if they have or will have immunodeficiency or immunosuppression 1, 3
The FDA label explicitly states that Shingrix is indicated for "adults aged 50 years and older" for routine prevention, and separately for "adults aged 18 years and older who are or will be at increased risk of HZ due to immunodeficiency or immunosuppression" 1.
Why Age 50?
The age threshold is based on:
- Disease epidemiology: Herpes zoster incidence and severity increase substantially with age, particularly after 50 years
- Clinical trial design: The pivotal ZOE-50 and ZOE-70 trials enrolled adults aged ≥50 years, demonstrating 97.2% vaccine efficacy in preventing herpes zoster 2
- Risk-benefit assessment: Younger immunocompetent adults have significantly lower baseline risk of herpes zoster and its complications
What About This 22-Year-Old?
For a healthy 22-year-old:
- No indication exists: This patient falls outside all approved and recommended age ranges
- Low baseline risk: Herpes zoster is uncommon in young immunocompetent adults
- No safety/efficacy data: Clinical trials did not include healthy adults under age 50
Exception: Immunocompromising Conditions
The only scenario where a 22-year-old would qualify is if they have:
- HIV infection
- Hematologic malignancies
- Solid organ or hematopoietic stem cell transplantation
- Autoimmune inflammatory rheumatic diseases requiring immunosuppressive therapy
- Other conditions causing immunodeficiency or requiring immunosuppressive medications 4, 5, 6, 3
If this patient is truly healthy without any immunocompromising conditions, Shingrix should not be administered.
Clinical Pearls
- The recombinant nature of Shingrix (non-live vaccine) makes it safe for immunocompromised patients, unlike the older live-attenuated Zostavax 4
- When indicated, Shingrix is given as a 2-dose series, with doses separated by 2-6 months (or 1-2 months for immunocompromised adults) 1
- Common adverse reactions include injection-site pain (83-88%), myalgia, fatigue, and headache, which are typically mild-to-moderate and transient 1, 7
Bottom line: Advise this patient that Shingrix vaccination should be deferred until age 50 years, unless they develop an immunocompromising condition in the interim.